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Abstract
Functional impairment of DNA damage response pathways leads to increased genomic instability.
Here we describe the centrosomal protein CEP152 as a new regulator of genomic integrity and
cellular response to DNA damage. Using homozygosity mapping and exome sequencing, we
identified CEP152 mutations in Seckel syndrome and showed that impaired CEP152 function
leads to accumulation of genomic defects resulting from replicative stress through enhanced
activation of ATM signaling and increased H2AX phosphorylation.
Maintenance of genomic integrity is required for cell survival and function. As the
accumulation of DNA damage has an important effect on cell viability, organisms have
evolved mechanisms to protect the integrity of DNA by inducing DNA damage responses
and cell cycle arrest or by triggering apoptosis1. Disruption of these mechanisms can lead to
increased genomic instability, which is a key factor for the development of cancer and is
involved in aging. Two important regulators of DNA-damage responses are the
phosphoinositide 3-kinase–related serine/threonine kinases ATM (Ataxia-Telangiectasia
Mutated) and ATR (Ataxia-Telangiectasia and Rad3 related)1,2. Whereas ATM is activated
in response to DNA double-strand breaks, ATR is involved mainly in responses to single-
stranded DNA induced by ultraviolet light damage or replication arrest. ATM and ATR both
trigger an overlapping set of cellular responses that promote cell cycle arrest and DNA
repair3.
Recently, it was reported that a hypomorphic ATR mutation is associated with embryonic
replicative stress, accelerated aging in mice and Seckel syndrome in humans4,5. Seckel
syndrome (MIM210600) is a heterogeneous autosomal recessive disorder characterized by a
proportionate short stature, severe microcephaly and mental retardation, and a typical ‘bird-
head’ facial appearance6. Initially, we clinically evaluated five consanguineous families with
Seckel syndrome originating from an isolated rural area in Turkey (Fig. 1, Supplementary
Figs. 1 and 2 and Supplementary Table 1). We genotyped DNA from four affected members
of three families using the 250K SNP Array (Affymetrix) and obtained a single maximum
log10 odds (LOD) score of 6.03 for a region between rs1598206 and rs2330591 on
chromosome 15q21.1–q21.2 (Fig. 1b). Subsequent fine mapping using microsatellite
markers confirmed shared homozygosity and a founder haplotype in a 3.4-Mb region
between markers D15S123 and D15S1017. This genomic region contains 28 known and
predicted genes. Microcephalic osteodysplastic primordial dwarfism type II (MOPDII,
MIM210720), which shows overlapping features with Seckel syndrome, was recently
associated with mutations in PCNT, the centrosomal pericentrin gene7,8. Hence, we
considered CEP152, the centrosomal protein 152 gene located in the critical region, to be a
highly relevant candidate gene.
Sequencing of all 27 exons of CEP152 (Supplementary Table 4) revealed a homozygous
splice donor-site mutation in intron 4, c.261+1G>C, which co-segregated with the founder
haplotype and the disease in all affected family members (Supplementary Fig. 3) and was
not found in 250 healthy Turkish control individuals. The c.261+1G>C mutation completely
disrupted the splice donor site, as shown through RT-PCR analysis of RNA from affected
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individuals. We found four different aberrant transcripts likely to cause loss of protein
function though partial functional activity of one mutant protein, Val86_Asn87del, could not
be excluded (Supplementary Fig. 4).
Independently, we identified CEP152 as the causative gene in a French individual with
Seckel syndrome of Turkish origin born to consanguineous parents through the use of an
exome sequencing strategy (Supplementary Methods). We identified seven new and
homozygous nonsense and essential splice-site variants that were expected to have a severe
impact on gene function (Supplementary Table 2). Of these seven variants, a G>C
transversion at the +1 position of a donor site was embedded within a ~35-Mb tract of
homozygosity on chromosome 15, which was the longest tract of homozygosity observed on
any autosome in this individual (Fig. 1c). None of the other variants were associated with a
large region of homozygosity. This mutation is the same c.261+1G>C Turkish founder
mutation in CEP152 described above. These data demonstrated that mutation identification
through exome sequencing, in conjunction with simultaneous analysis of homozygous
stretches, can be used as an efficient approach to gene identification in autosomal recessive
disorders.
In addition, sequencing CEP152 in further subjects with Seckel syndrome identified two
individuals that were compound heterozygous for likely loss-of-function mutations. One
subject of Italian origin from Germany was compound heterozygous for a nonsense
mutation, c.2034T>G (p.Tyr678X), and an intron 19-splice donor-site mutation, c.
2694+1G>T, leading to retention of the entire intron 19 in the CEP152 mRNA (r.
2694G_ins3581, Ile899LeufsX29) (Supplementary Fig. 5). Because the phenotype of this
subject was as severe as the phenotypes seen in the Turkish families, it is likely that the c.
261+1G>C Turkish founder mutation has similar functional consequences as the mutation
seen here. A subject from South Africa was compound heterozygous for a paternally
inherited 2-bp deletion, c.4210–4211delGT (p.Val1404fsX2, exon 27), and a maternally
inherited missense mutation, c.2000A>G (exon 15), affecting the highly conserved lysine at
position 667 (p.Lys667Arg) (Fig. 1d and Supplementary Fig. 3). Very recently, mutations in
CEP152 have been associated with microcephaly in an Eastern Canadian subpopulation9.
CEP152 encodes a 1,654 amino acid protein that was originally identified in a proteomic
screen of human centrosomes10. Analysis of the subcellular localization of asl (asterless),
the Drosophila ortholog of CEP152, has shown it to be associated with the periphery of
centrioles, where it is involved in the initiation of centriole duplication11. Expression of
CEP152 in HEK293T cells revealed fluorescence staining of the centrosomes, where it co-
localized with pericentrin (Fig. 2)12. To determine the functional effect of CEP152
deficiency on genomic stability, we analyzed the morphology of CEP152-deficient Seckel
fibroblasts during interphase and during different stages of mitosis. A substantial number of
Seckel fibroblasts contained multiple, differently sized nuclei and centrosomes, micronuclei
and fragmented centrosomes during interphase (Fig. 2a and Supplementary Fig. 6).
Metaphase karyotyping of CEP152-deficient Seckel lymphocytes showed aneuploidy in 15
out of a total 109 metaphase spreads (Fig. 2b). During metaphase, we observed incorrectly
aligned chromosomes, monopolar spindles with a single large centrosome, triple spindles
with differently sized and structurally compromised centrosomes, and prematurely separated
sister chromatids in Seckel cells. Statistical analysis revealed that CEP152 deficiency leads
to an increased number of cells containing multiple nuclei and centrosomes, fragmented
centrosomes and an increased frequency of aberrant cell divisions.
Moreover, the number of CEP152-deficient cells in telophase was decreased. Most
strikingly, CEP152-deficient cells appeared to be arrested at early anaphase, reflected by an
increased number of early anaphase figures in fixed Seckel populations when compared to
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the wildtype population (Supplementary Fig. 6f). This block may have resulted from
problems with chromatid alignment, uneven pulling forces in the spindle, or activation of a
checkpoint that responds to weakly attached or misaligned chromosomes. There did not
appear to be additional apoptosis at early anaphase. Taken together, these data clearly
showed centrosomal and mitotic aberrations caused by CEP152 mutations.
In addition, Seckel cells showed an overall increased sensitivity to oxidative stress and
responded to this stress with increased apoptosis (Supplementary Fig. 7). Cell cycle analysis
in CEP152 knockdown cells using short hairpin RNA suggested that CEP152 deficiency
delays S-phase entry. Furthermore, fewer Seckel cells progressed to the G2/M phase and an
increased proportion of Seckel cells stayed in G0/G1. These findings suggest altered ATR-
mediated checkpoint activity and increased replicative stress in CEP152-deficient cells.
In order to determine possible defects in DNA repair mechanisms, we measured the
mitomycin-C–induced sister chromatid exchange frequency. We observed a substantial
increase in chromosome instability in CEP152-deficient lymphocytes (Supplementary Table
3). In a yeast two-hybrid (Y2H) screen using an N-terminal deletion construct of CEP152 as
bait, the CDK2-interacting protein (CINP) was identified as an interaction partner of
CEP152 in three independent hits. We confirmed the CEP152-CINP interaction by using
complementary immunoprecipitation approaches, and we showed that CEP152
constitutively binds to CINP (Supplementary Fig. 8). We observed a weak nuclear staining
for both CEP152 and CINP (data not shown). CINP has recently been identified as a
genome maintenance protein13 that interacts with the ATR-interacting protein (ATRIP) and
has an important function in ATR-mediated checkpoint signaling. Silencing of CINP causes
increased γH2AX foci formation, suggesting that CINP contributes to the formation of a
functional unit in DNA damage response. The identification of CEP152 as a binding partner
of CINP provides additional evidence for an important role of CEP152 in DNA-damage
response and genome maintenance.
ATR-mediated phosphorylation of CHK1 and H2AX are the initial steps in response to
DNA damage and increased replicative stress14,15. We did not observe a detectable
alteration in hydroxyurea-induced phosphorylation of CHK1 in CEP152-deficient cells (Fig.
2d). However, we found that replicative stress leads to enhanced CHK2 phosphorylation in
Seckel cells (Supplementary Fig. 8), indicating an increased activation of ATM signaling
pathways. Furthermore, we found that formation of hydroxyurea-induced γH2AX foci in
CEP152-deficient cells was increased. Protein blot analysis confirmed that the levels of
γH2AX were considerably higher in hydroxyurea-treated CEP152-deficient cells as
compared to wildtype cells. There are likely to be additional mechanisms by which CEP152
might affect ATR checkpoint control and subsequently lead to increased replicative stress,
which causes a compensatory activation of CHK2 and γH2AX. Recent analysis of H2AX
phosphorylation in the ATRs/s Seckel mouse model indicated that γH2AX has been
substantially increased throughout embryonic development, particularly in tissues with a
high mitotic index5. In agreement with our results, a previous study suggested that
accumulated replicative stress can activate ATM-dependent DNA damage response and
thereby lead to increased H2AX phosphorylation5.
In conclusion, we identified the centrosomal protein CEP152 as a new protein involved in
the maintenance of genomic integrity and in the ability to respond to DNA damage.
Impaired CEP152 function leads to genomic instability and increased H2AX
phosphorylation, a measure of accumulated replicative stress. Our data further support the
essential link between genomic instability, as seen in individuals with Seckel syndrome, and
the activation of histone H2AX as response to increased replicative stress.
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Figure 1.
Clinical and molecular characterization of CEP152 Seckel subjects. (a) Clinical
characteristics of subjects 442, 443 and 586 presenting with microcephaly, sloping forehead,
high nasal bridge, beaked nose and retrognathia. Informed consents to publish the
photographs were obtained from the subjects’ parents. Cranial magnetic resonance imaging
of subjects 586 and 935 showing simplified gyri. (b) Genome-wide graphical view of LOD
scores using SNP array homozygosity mapping in four affected subjects, 442, 443, 586 and
633, indicated significant linkage to chromosome 15q21.1–q21.2. (c) Above, homozygosity
(blue line) was measured as the percent of homozygous sites within a sliding window of 100
variant sites, relative to the reference genome, obtained from the exome sequencing data.
CEP152 is located on chromosome 15, which harbors one of the longest stretches of
homozygosity in this genome. Below, the chromosomal locations of all single nucleotide
variants called on chromosome 15 are plotted against the genotype quality for that variant.
Homozygous variants are plotted in red, and heterozygous variants are plotted in black.
Homozygosity (blue line) is measured as the fraction of homozygous sites within a sliding
window of 50 variant sites (relative to the reference genome) called from the exome
sequencing data. (d) Above, the genomic structure of human CEP152. The position of each
mutation is shown on the coding DNA level. Below, the protein structure of CEP152 with
predicted coiled-coil domains (blue boxes) and Thr/Ser-phosphorylation sites (red). The
position and the predicted effects of the mutations on CEP152 are marked by arrows.
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Figure 2.
Characterization of CEP152 Seckel cells. (a) Mitotic morphology of CEP152 Seckel
fibroblasts. Immunofluorescence staining of CEP152 Seckel fibroblasts carrying the c.
261+1G>C mutation with antibodies against α-tubulin (green), pericentrin (red) and DAPI
staining of DNA (blue). Above, from left to right, control fibroblasts showing normal
mitotic morphology of interphase, metaphase, anaphase and telophase. Middle, Seckel
interphase cells containing three equally sized nuclei and two centrosomes without astral
microtubules (inset, tenfold magnification), two unseparated centrosomes per nucleus
without asters (inset, threefold magnification), fragmented centrosomes without asters and
micronuclei (inset, twofold magnification), and partially depolymerized microtubules
together with micronuclei in addition to a main nucleus. Below, abnormal Seckel
metaphases showing incorrectly aligned chromosomes on the metaphase plate, a monopolar
spindle with a large centrosome and reduced spindle, a tripolar spindle with differently sized
and structurally compromised centrosomes, and an abnormal Seckel telophase showing
defects in cytokinesis (inset, twofold magnification). Scale bars, 5 μm. (b) Aneuploid
metaphase karyotype of a CEP152 Seckel lymphocyte. (c) Centrosomal localization of
wildtype CEP152 in HEK293T cells expressing either GFP-tagged wildtype CEP152
(above) or GFP as a control (below). Additional staining was with pericentrin (red) and
DAPI (blue). (d) DNA-damage response in wildtype and Seckel fibroblasts. H2AX
phosphorylation of wildtype and CEP152 Seckel primary fibroblasts after treatment with
hydroxyurea (HU) (left). Protein blot analysis of HU-induced phosphorylation of CHK1
(Ser345) and H2AX (Ser139) (right). Equal protein loading was confirmed by re-probing of
the membranes with antibodies against CHK1 or H2AX and actin antibodies.
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